Commonwealth Equity Services LLC Has $979,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Commonwealth Equity Services LLC boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 62.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 6,497 shares of the company’s stock after purchasing an additional 2,491 shares during the period. Commonwealth Equity Services LLC’s holdings in TransMedics Group were worth $979,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group during the first quarter worth approximately $35,000. International Assets Investment Management LLC bought a new position in shares of TransMedics Group during the second quarter worth approximately $47,000. J.Safra Asset Management Corp increased its holdings in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC increased its holdings in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Entropy Technologies LP bought a new position in shares of TransMedics Group during the first quarter worth approximately $201,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $156.08 on Wednesday. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37. The firm has a fifty day simple moving average of $154.40 and a 200 day simple moving average of $127.98. The company has a market capitalization of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the firm earned ($0.03) earnings per share. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1.23 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMDX. Needham & Company LLC began coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Piper Sandler raised their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Cantor Fitzgerald started coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Stephens raised their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $171.44.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $109,770.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,247 shares of company stock valued at $9,650,880. Corporate insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.